| Name | Title | Contact Details |
|---|---|---|
Patricia Christiansen |
Sr. Director of Consumer Marketing Technology Infrastructure | Profile |
Precision Medicine. Precision Therapies.Hummingbird Bioscience is leading a bold new way of engineering precision biotherapeutics that can define the future of precision medicine. We focus on important biologically validated targets in cancer and autoi...
Ganix is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Singulex is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ViaCyte is a privately held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments to achieve glucose control targets and reduce the risk of hypoglycemia and diabetes-related complications. ViaCyte`s product candidates are based on directed differentiation of pluripotent stem cells into PEC-01 pancreatic islet progenitor cells, which are then implanted in durable and retrievable cell delivery devices. ViaCyte demonstrated that when effectively engrafted, PEC-01 cells can mature into glucose-responsive insulin producing cells in patients with type 1 diabetes. To accelerate and expand its efforts, ViaCyte has established collaborative partnerships with leading companies including CRISPR Therapeutics and W.L. Gore & Associates.
GrayBug® is a platform drug delivery company that is developing proprietary controlled release technologies for ophthalmic pharmaceutical indications. The company`s lead product is a polymer-drug biomolecular conjugate for the treatment of neovascular diseases, including age-related macular degeneration (AMD). GrayBug also has a proprietary platform technology that allows sustained drug delivery into various compartments of the eye while minimizing inflammation common with current controlled release technologies applied to the eye.